| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 141 | PREDICTIVE MARKERS OF IBD | US15544158 | 2016-01-22 | US20180024149A1 | 2018-01-25 | Eduardo Schiffrin; Viral Brahmbhatt; Francois-Pierre Martin; Ivan Montoliu Roura; Serge Andre Dominique Rezzi; Jalil Benyacoub |
| The invention relates to a method, a system and kit for identifying the sample of a patient having IBD or predicting the relapse of IBD in patients based on the measurement of biomarkers in a sample of the patient. The biomarkers can be lipids or amino acids or a combination thereof. | ||||||
| 142 | Means and Methods for Diagnosing Heart Failure in a Subject | US15507801 | 2015-09-01 | US20170285049A1 | 2017-10-05 | Philipp Schatz; Henning Witt; Martin Dostler; Susan Carvalho; Erik Peter; Philipp Ternes; Philipp Mappes; Hans Dirk; Tobias Daniel; Elvis Tahirovic; Hugo Katus; Norbert Frey; Tanja Weis |
| The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing heart failure in a subject based on determining the amounts of at least three biomarkers. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices. | ||||||
| 143 | BIOMARKERS FOR ASSESSING HIV | US15301913 | 2015-03-31 | US20170184619A1 | 2017-06-29 | ISMAEL DALE COTRIM GUERREIRO DA SILVA; EDSON GUIMARAES LOTURCO; RICOARDO SOUBIE DIAZ; THERESE KOAL |
| The present invention relates to metabolic biomarker sets for assessing HIV. In preferred embodiments, the present invention relates to the use of biomarker sets for screening and/or diagnosing HIV infection, for prediction of immunologic response of a mammalian subject to antiretroviral therapy and/or prognosis of HIV disease progression, and for monitoring of HIV disease activity in a mammalian subject. In other embodiments, the invention relates to methods for screening and/or diagnosing HIV infection, for prediction of immunologic response of a mammalian subject to antiretroviral therapy and/or prognosis of HIV disease progression, and for monitoring of HIV disease activity in a mammalian subject, as well as to a kit adapted to carry out the methods. By employing the specific biomarkers and the method according to the present invention it becomes possible to more properly and reliably assess HIV. In particular, it becomes possible to screen for and diagnose HIV in a patient with high accuracy and predict early in advance the patient's therapeutic response to antiretroviral therapy. | ||||||
| 144 | BIOMARKERS FOR ASSESSING HIV | US15387932 | 2016-12-22 | US20170160246A1 | 2017-06-08 | ISMAEL DALE COTRIM GUERREIRO DA SILVA; EDSON GUIMARAES LOTURCO; RICOARDO SOUBIE DIAZ; THERESE KOAL |
| The present invention relates to metabolic biomarker sets for assessing HIV. In preferred embodiments, the present invention relates to the use of biomarker sets for screening and/or diagnosing HIV infection, for prediction of immunologic response of a mammalian subject to antiretroviral therapy and/or prognosis of HIV disease progression, and for monitoring of HIV disease activity in a mammalian subject. In other embodiments, the invention relates to methods for screening and/or diagnosing HIV infection, for prediction of immunologic response of a mammalian subject to antiretroviral therapy and/or prognosis of HIV disease progression, and for monitoring of HIV disease activity in a mammalian subject, as well as to a kit adapted to carry out the methods. By employing the specific biomarkers and the method according to the present invention it becomes possible to more properly and reliably assess HIV. In particular, it becomes possible to screen for and diagnose HIV in a patient with high accuracy and predict early in advance the patient's therapeutic response to antiretroviral therapy. | ||||||
| 145 | USE OF LIPID PARTICLES IN MEDICAL DIAGNOSTICS | US14761587 | 2014-01-23 | US20170030935A9 | 2017-02-02 | Katherine B. LOUIE; Benjamin P. BOWEN; Trent R. NORTHEN |
| Disclosed herein are methods for identifying one or more diseased cells in a subject, methods for cancer diagnosis, methods for determining cancer progression in a subject and methods for assessing health status in a subject. | ||||||
| 146 | MARKER OF NEUROPATHIC GAUCHER'S DISEASE AND METHODS OF USE THEREOF | US15234364 | 2016-08-11 | US20170030926A1 | 2017-02-02 | Anthony FUTERMAN; Hila Zigdon |
| A biomarker of the neuronopathic types of Gaucher's disease (nGD) is provided, and use thereof for assisting the diagnosis of this form of the disease and its severity. In particular, use of the level of trans-membrane glycoprotein non-metastatic B (GPNMB) or a fragment thereof in the cerebrospinal fluid (CSF) as a diagnostic marker of nGD is provided. Further provided are methods for selecting drugs and assessing the efficacy of drugs and therapies for treating nGD. | ||||||
| 147 | LIPID BIOMARKERS OF HEALTHY AGEING | US15028244 | 2014-11-05 | US20160245786A1 | 2016-08-25 | Sebastiano Collino; Ivan Montoliu Roura; Françios-Pierre Martin; Fiona Camille Beguelin; Serge André Dominique Rezzi |
| In one aspect there is provided a method for predicting a risk of unhealthy ageing in a subject, comprising: (a) determining a level of two or more lipid biomarkers in a sample from the subject, wherein the biomarkers are selected from two or more of the following groups: (i) a triacylglycerol (TAG) from TAG (46:5) to TAG (54:3); (ii) an ether phosphatidylcholine (PC-O) from PC-O(28:0) to PC-O(38:6); (iii) a sphingomyelin (SM) from SM (33:1) to SM(50:1); (iv) a phosphatidylcholine (PC) from PC (32:1) to PC (40:5); (v) a phosphatidylinositol (PI) from PI (36:1) to PI (38:3); (vi) a phosphatidylethanolamine (PE) from PE (36:2) to PE (38:4); and (b) comparing the levels of the biomarkers in the sample to reference values; wherein the levels of the biomarkers in the sample compared to the reference values are indicative of the risk of unhealthy ageing in the subject. | ||||||
| 148 | USE OF LIPID PARTICLES IN MEDICAL DIAGNOSTICS | US14761587 | 2013-01-23 | US20160003855A1 | 2016-01-07 | Katherine B. LOUIE; Benjamin P. BOWEN; Trent R. NORTHEN |
| Disclosed herein are methods for identifying one or more diseased cells in a subject, methods for cancer diagnosis, methods for determining cancer progression in a subject and methods for assessing health status in a subject. | ||||||
| 149 | CERAMIDES AND THEIR USE IN DIAGNOSING CVD | US14677595 | 2015-04-02 | US20150362513A1 | 2015-12-17 | Reijo Laaksonen |
| The present invention inter alia provides a method, and use thereof, of predicting CV complications such as AMI, ACS, stroke, and CV death by determining the concentrations of at least one ceramide of Group A and at least one ceramide of Group B in a biological sample and comparing those concentrations to a control. Finding a decreased concentration of at least one Group A ceramide and an increased concentration of at least one Group B ceramide indicates that the subject has an increased risk of developing one or more CV complications. Also provided are a newly identified subset of ceramide molecules, labelled versions thereof, and kits and compositions comprising the same for use in predicting and/or diagnosing CV complications. | ||||||
| 150 | METHODS AND APPARATUS FOR THE ANALYSIS OF FATTY ACIDS | US14762997 | 2014-01-24 | US20150331001A1 | 2015-11-19 | Michael D. Jones; Giorgis Mezengie Isaac; Isabelle Francois; Warren B. Potts; James I. Langridge |
| Exemplary embodiments of the present disclosure relate to CO2-based chromatography for the efficient and precise separation of fatty acids. The present disclosure is based, in part, on the discovery that a CO2-based chromatography system with features, such as, e.g., improved pressure stability, improved sample injection, and superior column packing materials, reproducibly resolve fatty acids. | ||||||
| 151 | Means and Methods for Diagnosing and Monitoring Heart Failure in a Subject | US14235513 | 2012-07-27 | US20150160238A1 | 2015-06-11 | Regina Reszka; Jens Fuhrmann; Jürgen Kastler; Bianca Bethan; Martin Kluttig; Hugo A. Katus; Norbert Frey; Johanna Wolf; Tanja Weis |
| The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing heart failure in a subject and a method for monitoring progression or regression of heart failure in a subject. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices. | ||||||
| 152 | ASSAYS FOR DETECTING MODIFIED COMPOUNDS | US14296756 | 2014-06-05 | US20150005471A1 | 2015-01-01 | ELAZAR RABBANI; JOSHUA RABBANI; PRAVEEN PANDE; JANNIS G. STAVRIANOPOULOS |
| Provided are methods and compositions which are useful for separating, isolating, detecting, and quantifying compounds of interest which have been modified chemically, enzymatically or catalytically from other compounds which have not been so modified. The modifications may take the form of functional groups which are gained, lost or retained by the compounds of interest. | ||||||
| 153 | ANTIBODY DESIGN USING ANTI-LIPID ANTIBODY CRYSTAL STRUCTURES | US13793255 | 2013-03-11 | US20130261287A1 | 2013-10-03 | Roger A. SABBADINI; Jonathan Michael WOJCIAK; Tom HUXFORD |
| Methods for designing optimized antibodies, including optimized humanized or human antibodies, to target bioactive lipids are provided. These methods may be performed in silico and may be intended to enhance binding affinity of an antibody to its original target lipid, and/or to alter binding specificity. Antibodies produced by these methods are also provided, as are methods for using them. | ||||||
| 154 | Method Of Treating Acute Lung Injury Using Sphingosine 1 Phosphate Analogs Or Sphingosine 1 Phosphate Receptor Agonists | US13582627 | 2011-03-03 | US20130079309A1 | 2013-03-28 | Joe G.N. Garcia; Steven M. Dudek |
| The invention provides methods for treating or reducing the risk of developing acute lung injury manifested by increased vascular permeability. Also provided are pharmaceutical compositions comprising an FTY720 analog or derivative and/or SEW 2871 for use in the disclosed methods. The invention also provides methods for treating or reducing the risk of developing acute lung injury resulting from dysregulation of ceramide/sphingolipid pathway, more specifically, acute lung injury resulting from radiation. | ||||||
| 155 | Compositions and methods for the modulation of sphingolipid metabolism and/or signaling | US10348052 | 2003-01-17 | US07674580B2 | 2010-03-09 | Julie D Saba; Henrik Fyrst |
| Compositions, methods and kits for diagnosing and treating cancer and muscular disorders are provided. Therapeutic compositions may comprise agents that modulate sphingolipid metabolism and/or signaling pathways. Such compositions may be administered to a mammal afflicted with cancer. Diagnostic methods and kits may employ an agent suitable for detecting alterations in endogenous genes involved in sphingolipid metabolism. Such methods and kits may be used to detect the presence of a cancer or to evaluate the prognosis of a known disease. SPL polypeptides, polynucleotides and antibodies are also provided. | ||||||
| 156 | ENZYMATIC METHODS FOR MEASURING PLASMA AND TISSUE SPHINGOMYLELIN AND PHOSPHATIDYLCHOLINE | US12097380 | 2006-12-13 | US20090148877A1 | 2009-06-11 | Xian-Cheng Jiang; Mohammad Reza Hojjati |
| A method for measuring sphingomyelin and phosphatidylcholine comprising incubating sphingomyelin and phosphatidylcholine with bacterial sphingomyelinase and bacterial phospholipase D, alkaline phosphatase, choline oxidase, peroxidase, N-Ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline, and 4-aminoantipyrine, preferably for about 45 minutes. A blue dye is generated. | ||||||
| 157 | Method for detecting sphingosine-1-phosphate (S1P) for cancer detection | US10133012 | 2002-04-26 | US06716595B2 | 2004-04-06 | Michael K. Skinner; Jodi L. Johnson; Jeff A. Parrott |
| The present invention relates to non-radioactive enzymatic methods for detecting Sphingosine-1-Phosphate (S1P) in biological fluids. The present invention further relates to a method of detecting the presence of cancer in a patient by the use of these and other methods of detecting S1P in biological samples from a patient. | ||||||
| 158 | Compositions and methods for the modulation of sphingolipid metabolism and/or signaling | US10348052 | 2003-01-17 | US20030219782A1 | 2003-11-27 | Julie D. Saba; Henrik Fyrst |
| Compositions, methods and kits for diagnosing and treating cancer and muscular disorders are provided. Therapeutic compositions may comprise agents that modulate sphingolipid metabolism and/or signaling pathways. Such compositions may be administered to a mammal afflicted with cancer. Diagnostic methods and kits may employ an agent suitable for detecting alterations in endogenous genes involved in sphingolipid metabolism. Such methods and kits may be used to detect the presence of a cancer or to evaluate the prognosis of a known disease. SPL polypeptides, polynucleotides and antibodies are also provided. | ||||||
| 159 | Novel Assays | US10168262 | 2002-12-17 | US20030129664A1 | 2003-07-10 | Sultan Ahmad; Paola Lembo; Phillippe Walker |
| The present invention is directed to assays that can be used to screen for compounds that act as agonists or antagonists of sphingosine-1 PO4. The assays are based upon the binding of sphingosine-1 PO4 to the RP-23 receptor. | ||||||
| 160 | Determination of biological characteristics of embryos fertilized in vitro by assaying for bioactive lipids in culture media | US10309445 | 2002-12-03 | US20030129580A1 | 2003-07-10 | Jeff A. Parrott |
| The present invention provides methods for determining various biological characteristics of in vitro fertilized embryos, including overall embryo health, implantability, and increased likelihood of developing successfully to term. More specifically, the present invention concerns analyzing media specimens of in vitro fertilization cultures for levels of bioactive lipids in order to determine these characteristics. | ||||||
QQ群二维码
意见反馈
意见反馈